Catherine S Diefenbach

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.

M. Shadman, L. Nastoupil, S. Assouline, 2024, Journal of Clinical Oncology.

Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.

M. Shadman, S. Assouline, D. El-Sharkawi, 2023, Clinical lymphoma, myeloma & leukemia.

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

E. Cerami, D. D. Del Valle, S. Kim-Schulze, 2024, Cancer research communications.

The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.

Catherine S Diefenbach, Gaurav Varma, 2024, Seminars in hematology.

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

E. Wakeland, F. Fattah, Chengsong Zhu, 2024, Oncoimmunology.